6‑Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β‑Lactam Antibiotics

Pseudomonas aeruginosa, a major cause of nosocomial infections, is considered a paradigm of antimicrobial resistance, largely due to hyperproduction of chromosomal cephalosporinase AmpC. Here, we explore the ability of 6-pyridylmethylidene penicillin-based sulfones 1–3 to inactivate the AmpC β-lacta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2021-05, Vol.64 (9), p.6310-6328
Hauptverfasser: Vázquez-Ucha, Juan C, Rodríguez, Diana, Lasarte-Monterrubio, Cristina, Lence, Emilio, Arca-Suarez, Jorge, Maneiro, María, Gato, Eva, Perez, Astrid, Martínez-Guitián, Marta, Juan, Carlos, Oliver, Antonio, Bou, German, González-Bello, Concepción, Beceiro, Alejandro
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pseudomonas aeruginosa, a major cause of nosocomial infections, is considered a paradigm of antimicrobial resistance, largely due to hyperproduction of chromosomal cephalosporinase AmpC. Here, we explore the ability of 6-pyridylmethylidene penicillin-based sulfones 1–3 to inactivate the AmpC β-lactamase and thus rescue the activity of the antipseudomonal ceftazidime. These compounds increased the susceptibility to ceftazidime in a collection of clinical isolates and PAO1 mutant strains with different ampC expression levels and also improved the inhibition kinetics relative to avibactam, displaying a slow deacylation rate and involving the formation of an indolizine adduct. Bromide 2 was the inhibitor with the lowest K I (15.6 nM) and the highest inhibitory efficiency (k inact/K I). Computational studies using diverse AmpC enzymes revealed that the aromatic moiety in 1–3 targets a tunnel-like site adjacent to the catalytic serine and induces the folding of the H10 helix, indicating the potential value of this not-always-evident pocket in drug design.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.1c00369